AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes

Genes Chromosomes and Cancer

Volumn 43, Issue 2, 2005, Pages 113-127

  Haferlach, Torsten ^a   Kohlmann, Alexander ^a   Schnittger, Susanne ^a   Dugas, Martin ^b   Hiddemann, Wolfgang ^a   Kern, Wolfgang ^a   Schoch, Claudia ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD CLOTTING; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE CLASSIFICATION; DNA MICROARRAY; GENE EXPRESSION; GENE MUTATION; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 17744366190     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20175     Document Type: Article

References (72)

1. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. 2002. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30: 41-47.
2. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25:25-29.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. 1976. Proposals for the classification of the acute leukaemias. French- American-British (FAB) co-operative group. Br J Haematol 33:451-458.
4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. 1980. A variant form of hypergranular promyelocytic leukaemia (M3) [letter]. Br J Haematol 44:169-170.
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Willman CL. 2000. Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17). Leukemia 14:1197-1200.
6. Bock BC, Vacratsis PO, Qamirani E, Gallo KA. 2000. Cdc42-induced activation of the mixed-lineage kinase SPRK in vivo. Requirement of the Cdc42/Rac interactive binding motif and changes in phosphorylation. J Biol Chem 275:14231-14241.
7. Boxer LA, Smolen JE. 1988. Neutrophil granule constituents and their release in health and disease. Hematol Oncol Clin North Am 2:101-134.
8. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, Dohner H, Pollack JR. 2004. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:1605-1616.
9. Busse WW. 1998. Leukotrienes and inflammation. Am J Respir Grit Care Med 157:8210-8213.
10. Craig W, Poppema S, Little MT, Dragowska W, Lansdorp PM. 1994. CD45 isoform expression on human haemopoietic cells at different stages of development. Br J Haematol 88:24-30.
11. Debernardi S, Lillington DM, Chaplin T, Tomlinson S, Amess J, Rohatiner A, Lister TA, Young BD. 2003. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 37:149-158.
12. Degos L, Wang ZY. 2001. All trans retinoic acid in acute promyelocytic leukemia. Oncogene 20:7140-7145.
13. Downing JR, Shannon KM. 2002. Acute leukemia: a pediatric perspective. Cancer Cell 2:437-445.
14. Dugas M, Schoch C, Schnittger S, Haferlach T, Danhauser-Riedl S, Hiddemann W, Messerer D, Uberla K. 2001. A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping. Leukemia 15:1805-1810.
15. Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868.
16. Etienne-Manneville S. 2004. Cdc42 - the centre of polarity. J Cell Sci 117:1291-1300.
17. Evans CA, Ariffin S, Pierce A, Whetton AD. 2002. Identification of primary structural features that define the differential actions of IL-3 and GM-CSF receptors. Blood 100:3164-3174.
18. Foley R, Soamboonsrup P, Carter RF, Benger A, Meyer R, Walker I, Wan Y, Patterson W, Orzel A, Sunisloe L, Leber B, Neame PB. 2001. CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/ hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol 67:34-41.
19. Fukata M, Watanabe T, Noritake J, Nakagawa M, Yamaga M, Kuroda S, Matsuura Y, Iwamatsu A, Perez F, Kaibuchi K. 2002. Rac1 and Cdc42 capture microtubules through IQGAP1 and CLIP-170. Cell 109:873-885.
20. Furukawa Y, Nakatsuru S, Nagafuchi A, Tsukita S, Muto T, Nakamura Y, Horii A. 1994. Structure, expression and chromosome assignment of the human catenin (cadherin-associated protein) alpha 1 gene (CTNNA1). Cytogenet Cell Genet 65:74-78.
21. Gilliland DG, Griffin JD. 2002. The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532-1542.
22. Gilliland DG, Tallman MS. 2002. Focus on acute leukemias. Cancer Cell 1:417-420.
23. Goll DE, Thompson VF, Li H, Wei W, Cong J. 2003. The calpain system. Physiol Rev 83:731-801.
24. Golomb HM, Testa JR, Vardiman JW, Butler AE, Rowley JD. 1979. Cytogenetic and ultrastructural features of de novo acute promyelocytic leukemia; The university of Chicago experience (1973-1978). Cancer Genet Cytogenet 1:69-78.
25. Grimwade D, Enver T. 2004. Acute promyelocytic leukemia: where does it stem from? Leukemia 18:375-384.
26. Grimwade D, Haferlach T. 2004. Gene-expression profiling in acute myeloid leukemia. N Engl J Med 350:1676-1678.
27. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, Howe K, Dastugue N, Jansen J, Radford Weiss I, Lo Coco F, Lessard M, Hernandez JM, Delabesse E, Head D, Liso V, Sainty D, Flandrin G, Solomon E, Birg F, Lafage Pochitaloff M. 2000. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies". Blood 96:1297-1308.
28. Haferlach T, Schoch C. 2002. Modern techniques in leukemia diagnosis. Internist 43:1190-1202.
29. Haferlach T, Kohlmann A, Kern W, Hiddemann W, Schnittger S, Schoch C. 2003. Gene expression profiling as a tool for the diagnosis of acute leukemias. Semin Hematol 40:281-295.
30. Hirata RK, Chen ST, Weil SC. 1993. Expression of granule protein mRNAs in acute promyelocytic leukemia. Hematol Pathol 7:225-238.
31. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 2001. Lyon, France: IARC Press.
32. Jandl JH. 1996. Textbook of hematology. Boston: Little, Brown and Company.
33. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, Ley TJ, Gilliland DG. 2002. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 99:8283-8288.
34. Kern W, Danhauser-Riedl S, Ratei R, Schnittger S, Schoch C, Kolb HJ, Ludwig WD, Hiddemann W, Haferlach T. 2003a. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry to define leukemia-associated immunophenotypes and determine their frequencies in normal bone marrow. Haematologica 88:646-653.
35. Kern W, Kohlmann A, Wuchter C, Schnittger S, Schoch C, Mergenthaler S, Ratei R, Ludwig WD, Hiddemann W, Haferlach T. 2003b. Correlation of protein expression and gene expression in acute leukemia. Cytometry 55B:29-36.
36. Kohlmann A, Schoch C, Schnittger S, Dugas M, Hiddemann W, Kern W, Haferlach T. 2003. Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer 37:396-405.
37. Kohlmann A, Schoch C, Dugas M, Rauhut S, Weninger F, Schnittger S, Kern W, Haferlach T. 2005. Pattern robustness of diagnostic gene expression signatures in leukemia. Genes Chromosomes Cancer 42:299-307.
38. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H, Staib P, Heyll A, Seifarth W, Saussele S, Fonatsch C, Gassmann W, Ludwig WD, Hochhaus A, Beelen D, Aul C, Sauerland MC, Heinecke A, Hehlmann R, Wormann B, Hiddemann W, Buchner T. 2000. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 14:1362-1370.
39. Liu ET, Karuturi KR. 2004. Microarrays and clinical investigations. N Engl J Med 350:1595-1597.
40. Liu G, Loraine AE, Shigeta R, Cline M, Cheng J, Valmeekam V, Sun S, Kulp D, Siani-Rose MA. 2003. NetAffx: Affymerrix probe-sets and annotations. Nucleic Acids Res 31:82-86.
41. Mardia KV, Kent JT, Bibby JM. 1979. Multivariate analysis. London: Academic Press.
42. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 14:1156-1166.
43. McKeon FD, Kirschner MW, Caput D. 1986. Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins. Nature 319:463-468.
44. Miller LD, Long PM, Wong L, Mukherjee S, McShane LM, Liu ET. 2002. Optimal gene expression analysis by microarrays. Cancer Cell 2:353-361.
45. Miserez AR, Cao G, Probst LC, Hobbs HH. 1997. Structure of the human gene encoding sterol regulatory element binding protein 2 (SREBF2). Genomics 40:31-40.
46. Mistry AR, Pedersen EW, Solomon E, Grimwade D. 2003. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 17:71-97.
47. Nishizawa K, Freund C, Li J, Wagner G, Reinherz EL. 1998. Identification of a proline-binding motif regulating CD2-triggered T lymphocyte activation. Proc Natl Acad Sci USA 95:14897-14902.
48. Orfao A, Ortuno F, de Santiago M, Lopez A, San Miguel J. 2004. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry 58A:62-71.
49. Pellizzoni L, Yong J, Dreyfuss G. 2002. Essential role for the SMN complex in the specificity of snRNP assembly. Science 298:1775-1779.
50. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, Liu HC, Mahfouz R, Raimondi SC, Lenny N, Patel A, Downing JR. 2003. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102:2951-2959.
51. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz Mediavilla J, Bolufer P, Barragan E, Terol MJ, Gonzalez JD, Colomer D, Chillon C, Rivas C, Gomez T, Ribera JM, Bornstein R, Roman J, Calasanz MJ, Arias J, Alvarez C, Ramos F, Deben G. 1999. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 94:3015-3021.
52. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, Haferlach T, Hiddemann W 2002. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59-66.
53. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. 2003. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 102:2746-2755.
54. Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, Mergenthaler S, Kern W, Hiddemann W, Eils R, Haferlach T. 2002a. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sei USA 99:10008-10013.
55. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. 2002b. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 16:53-59.
56. Scoggan KA, Nicholson DW, Ford-Hutchinson AW. 1996. Regulation of leukotriene-biosynthetic enzymes during differentiation of myelocytic HL-60 cells to eosinophilic or neutrophilic cells. Eur J Biochem 239:572-578.
57. Staudt LM. 2002. It's ALL in the diagnosis. Cancer Cell 1:109-110.
58. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440-9445.
59. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC. 1995. Cloning and functional analysis of BAG-I: a novel Bcl-2-binding protein with anti-cell death activity. Cell 80:279-284.
60. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. 2002. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-4302.
61. Testa JR, Golomb HM, Rowley JD, Vardiman JW, Sweet DL, Jr. 1978. Hypergranular promyelocytic leukemia (APL): cytogenetic and ultrastructural specificity. Blood 52:272-280.
62. Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, Latagliata R, Mariani G, Rossini A, Battistini A, Lo-Coco F, Peschle C. 2002. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 100:2980-2988.
63. Thompson A, Quinn MF, Grimwade D, O'Neill CM, Ahmed MR, Grimes S, McMullin MF, Cotter F, Lappin TR. 2003. Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR. Blood 101:1558-1565.
64. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sei USA 98:5116-5121.
65. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R. 2004. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628.
66. Vapnik, V. Statistical Learning Theory. 1998. New York: Wiley.
67. Villadangos JA, Ploegh HL. 2000. Proteolysis in MHC class II antigen presentation: who's in charge? Immunity 12:233-239.
68. Watanabe R, Wada H, Miura Y, Murata Y, Watanabe Y, Sakakura M, Okugawa Y, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Shiku H, Nobori T 2001. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost 7:229-233.
69. Watts C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15:821-850.
70. Wydner KL, McNeil JA, Lin F, Worman HJ, Lawrence JB. 1996. Chromosomal assignment of human nuclear envelope protein genes LMNA, LMNB1, and LBR by fluorescence in situ hybridization. Genomics 32:474-478.
71. Yagi T, Morimoto A, Eguchi M, Hibi S, Sako M, Ishii E, Mizutani S, Imashuku S, Ohki M, Ichikawa H. 2003. Identification of a gene expression signature associated with pediatric AML prognosis. Blood 102:1849-1856.
72. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L, Downing JR. 2002. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143.